(Press-News.org) The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that lines the joints.
Sarcoma oncologist William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), led the international phase 3 MOTION trial that resulted in the drug’s approval. Vimseltinib is a type of targeted therapy called a kinase inhibitor and is taken as a pill.
“This approval is an exciting advance for patients with TGCT, who need better treatment options,” Dr. Tap says. “TGCT can be a very challenging disease. Although it is usually not life-threatening, it can have devastating effects on someone’s quality of life. After being diagnosed, people must live with this disease the rest of their lives, and it can cause a lot of pain and disability.”
TGCT, which is also called pigmented villonodular synovitis (PVNS), is not considered a cancer because it doesn’t spread to other parts of the body. Some people with the disease require multiple surgeries, even amputations. It is usually diagnosed in people in their 20s and 30s and is more common in women than in men.
Vimseltinib Benefits More Than Two-Thirds of Patients
Dr. Tap previously presented findings from the MOTION trial in June 2024 at the annual meeting of the American Society of Clinical Oncology. The research was also published in The Lancet at the time of his presentation, and he was co-corresponding author of the paper.
That study included 123 patients, 83 of whom got vimseltinib and 40 of whom got a placebo. The investigators reported that 67% of patients receiving vimseltinib had measurably reduced tumor volume, compared with none in the placebo group.
Additionally, patients in the trial who received vimseltinib reported improvement in several important measures, including:
Range of motion
Physical function
Joint stiffness
Pain
Overall health
Vimseltinib Has Fewer Side Effects than Pexidartinib
Dr. Tap previously led clinical trials for another drug for TGCT, called pexidartinib (Turalio®). That drug received approval from the FDA in 2019. But because it can cause liver damage in some patients, investigators sought additional options.
This trial found that vimseltinib had far fewer side effects than pexidartinib. The most common ones were swelling, rash, headaches, and feeling tired, but none were severe.
Importantly, the drug did not appear to cause liver injury in any patients who received it. This is significant because patients need to stay on these medicines long-term to keep their tumors under control.
“We believe that vimseltinib is another wonderful option to consider in treating people with TGCT,” Dr. Tap says.
The MOTION trial was funded by Deciphera Pharmaceuticals.
Dr. Tap’s financial disclosures are available on his webpage.
END
FDA approves vimseltinib for tenosynovial giant cell tumor (TGCT)
2025-02-19
ELSE PRESS RELEASES FROM THIS DATE:
Columbia Climate School launches M.S. in Climate Finance
2025-02-19
The Columbia Climate School has announced the first master’s degree program in the United States for climate finance. In close collaboration with the Columbia Business School, this interdisciplinary degree will drive impactful solutions to the climate crisis through advanced financial tools and scientific knowledge. This is the third master’s program announced by the Climate School, in addition to an M.A. in Climate and Society and an M.S. in Climate degree.
“The world needs problem-solvers to address the global climate crisis,” said Alexis Abramson, dean of the Columbia Climate School. “Everyone ...
MD Anderson receives nearly $23 million in CPRIT funding for cancer research, faculty recruitment
2025-02-19
HOUSTON ― The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to advance new breakthroughs in discovery, translational, clinical and prevention science. In addition, CPRIT awarded $2 million for the recruitment of one first-time, tenure-track faculty member.
“We sincerely appreciate CPRIT’s continued funding of impactful cancer research that will help us achieve our mission to end cancer,” said ...
A new way to observe electrons in motion
2025-02-19
Electrons oscillate around the nucleus of an atom on extremely short timescales, typically completing a cycle in just a few hundred attoseconds (one attosecond is a quintillionth of a second). Because of their ultrafast motions, directly observing electron behavior in molecules has been challenging. Now researchers from UC San Diego’s Department of Chemistry and Biochemistry have suggested a new method to make visualizing electron motion a reality.
This new method describes an experimental concept called ultrafast vortex electron diffraction, which allows ...
Study reveals palm trees once thrived in subarctic Canada
2025-02-19
New London, Conn. — A new study by Connecticut College provides strong evidence that palm trees once thrived in subarctic Canada, reshaping scientific understanding of past Arctic climates.
Conn Professor Peter Siver’s research, published in the journal Annals of Botany, confirms that during the late early Eocene—approximately 48 million years ago—this region maintained warm temperatures year-round, even during months of winter darkness. The work was done in collaboration with colleagues from Canada and Poland.
Siver’s team identified fossilized phytoliths—microscopic ...
Is smoking tied to unexplained stroke in younger adults?
2025-02-19
MINNEAPOLIS — Smoking, particularly heavy smoking, is linked to some unexplained strokes in younger adults, mainly in male individuals and in people ages 45 to 49, according to a study published in the February 19, 2025, online issue of Neurology® Open Access, an official journal of the American Academy of Neurology.
A stroke with no known cause, called a cryptogenic stroke, is a type of ischemic stroke caused by a blockage of blood flow, but it is unclear what has caused the blockage. Symptoms include weakness, trouble speaking and vision problems. Strokes can be fatal. Most strokes occur after age 65.
“While smoking has long been linked to ischemic stroke, ...
Princeton Chemistry demonstrates high-performance Sodium-ion cathode towards new battery technology
2025-02-19
For decades, scientists have sought ways to counter our dependence on lithium-ion batteries. These traditional, rechargeable batteries energize today’s most ubiquitous consumer electronics – from laptops to cell phones to electric cars. But raw lithium is expensive and is often sourced through fragile geopolitical networks.
This month, Princeton University’s Dincă Group announces an exciting alternative that relies on an organic, high-energy cathode material to make sodium-ion batteries, advancing the likelihood that this technology will find commercialization with safe, cheaper, more sustainable components.
While scientists ...
New study links dust storms to increased emergency department visits in the U.S. Southwest
2025-02-19
DENVER - A new research study highlights the significant health risks associated with dust storms, revealing an increase in emergency department (ED) visits for respiratory and cardiovascular conditions, as well as motor vehicle accidents, in three Southwestern U.S. states. The study, which was led at National Jewish Health was published this month in JAMA Network Open.
Researchers at National Jewish Health, Emory University and the University of Colorado analyzed over 33,500 ED visits across Arizona, California and Utah from 2005 to 2018. The findings ...
Stopping asthma in its tracks
2025-02-19
LA JOLLA, CA—Current asthma treatments don't work in all patients, and they don't provide long-term relief from potentially deadly asthma attacks.
Scientists at La Jolla Institute for Immunology (LJI) are advancing a new kind of therapy. According to a recent study published in the Journal of Allergy and Clinical Immunology, their approach holds promise for providing long-lasting relief for people with asthma—and it may be useful for dampening immune inflammation in general.
The researchers have developed two therapeutic ...
Chlorine plus UV light degrades toxins caused by harmful algae blooms
2025-02-19
Treatment plants use a combination of tools to keep toxins and contaminants out of drinking water.
Researchers with the University of Cincinnati examined two such tools in addressing a toxin produced by harmful algae blooms, which are becoming increasingly common in waters around the world.
Blue green algae can reproduce en masse in waters laden with nitrogen, phosphorus or other excess nutrients. These algae “blooms” also can form when water levels drop during droughts or when bottom sediments heavy with nutrients get churned up in a storm, said Minghao Kong, a doctoral graduate of UC’s ...
In Denmark, rural cat owners are neutering their cats and allowing them indoor access
2025-02-19
Cat owners in the Denmark countryside are increasingly managing their cats in the same way as urban cat owners, resulting in fewer unwanted kittens being born, according to a study published February 19, 2025, in the open-access journal PLOS One by Peter Sandøe from the University of Copenhagen, Denmark, and colleagues.
Populations of unowned domestic cats – whether unsocialized feral cats that have never lived with humans, or socialized cats that have strayed or been abandoned – are regarded as problematic in many countries. It is argued that they are a nuisance, that they transmit disease to humans, owned cats and ...